Clinical Trial Update: A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating ASP2215 in combination with erlotinib in EGFR activating mutation-positive advanced non-small-cell lung cancer with acquired resist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASP2215
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Non-Small-Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-02-15